Serotonin toxicity of serotonergic psychedelics

Serotonin toxicity (ST), also called serotonin syndrome, is a drug-induced toxidrome resulting from excessive serotonin (5-HT) neurotransmission. Malcolm and colleagues describe that life-threatening ST is uncommon but most likely when serotonin-releasing agents (SRAs) or serotonin reuptake inhibitors (SRIs) are combined with agents that prevent serotonin metabolism, notably monoamine oxidase inhibitors (MAOIs). A broad range of serotonergic psychedelics (natural tryptamines and phenethylamines, classic and novel compounds) act at 5-HT2A receptors and thus may produce somatic and psychological effects that overlap with mild ST. Given increasing clinical investigation of serotonergic psychedelics for psychiatric disorders—conditions commonly treated with serotonergic psychotropics such as SSRIs, SNRIs, TCAs, trazodone and others—there is a practical need to clarify the risk of ST from drug–drug combinations. This review sets out to: describe the clinical spectrum of serotonin-related adverse reactions and diagnostic criteria; summarise reported interactions between psychedelics and serotonergic medications; explain pharmacological mechanisms that increase or reduce the risk of severe toxicity; and outline management strategies for ST. The authors frame their synthesis as a critical evaluation of the literature intended to inform safety considerations as psychedelics move into therapeutic contexts.

The extracted text identifies the article as a review but does not provide a clear, explicit methods section describing a systematic search strategy, databases searched, inclusion/exclusion criteria, or a formal meta-analytic approach. Therefore, the exact method for selecting and appraising the literature is not reported in the available extraction. What is evident from the text is that the authors conducted a narrative synthesis drawing on case reports, poison-control data, pharmacology studies (including receptor and in vitro functional assays), and clinical trial experience. The review emphasises mechanistic pharmacology (effects on SERT, VMAT2, 5-HT2A activation efficacy, MAO inhibition and CYP interactions) and integrates observational evidence (poison centre trends, case series) with experimental findings to stratify risk across drug combinations. When specific trials or reports are described (for example, small clinical trials combining SRIs and MDMA, and clinical trials of MDMA or psilocybin that excluded concomitant serotonergic medications), the extraction does not supply systematic details about the selection or number of such studies.

Malcolm and colleagues organise findings around a clinical spectrum of serotonin-related effects, diagnostic criteria, psychedelic toxidromes, pharmacologic mechanisms, and management recommendations. Spectrum and diagnosis: Serotonin-related adverse reactions range from mild, self-limited symptoms (insomnia, nausea, anxiety, diarrhoea) to severe life-threatening ST featuring neuroexcitation (myoclonus, rigidity), marked mental-status changes (agitation, confusion, coma), extreme and fluctuating vital signs, hyperthermia and seizures. The authors note severe complications can include metabolic acidosis, rhabdomyolysis, renal failure, disseminated intravascular coagulation, multi-organ failure and ARDS. Symptom onset is typically rapid, often within 1–6 hours of acute ingestion and usually within 24 hours. Diagnostic frameworks are compared: Sternbach’s criteria (1991) and the Hunter criteria (2003), with the latter cited as more sensitive (84% vs 75%) and slightly more specific (97% vs 96%) and therefore the preferred clinical tool. Hunter’s algorithm emphasises clonus (spontaneous, inducible or ocular) and hyperreflexia paired with secondary features such as agitation, diaphoresis, tremor, hypertonia and hyperthermia (> 38 °C). Psychedelic effects versus ST: Many expected somatic effects of psychedelics—mydriasis, mild tremor, altered temperature sensation and gastrointestinal upset—overlap with mild serotonergic reactions and reflect 5-HT2A agonism. The authors stress the clinical challenge of distinguishing anticipated psychedelic somatic effects from evolving ST: features that should prompt concern include myoclonus or seizures, pronounced hyperthermia (≥ 40 °C cited as particularly severe), sustained or atypically intense symptoms beyond the expected drug duration, marked rigidity, or coma. Epidemiology and toxidromes: Serious toxicity from psychedelics is presented as rare in uncontrolled settings. Poison-control data indicate most calls involve younger individuals (adolescents 13–19 for LSD and psilocybin; median/mean age about 21 for ayahuasca and MDMA). Factors associated with severe outcomes include excessive dosing, adulteration (e.g., NBOMe sold as LSD), risky drug combinations, re-dosing patterns, unsafe environments, and police restraint. The authors cite a review of NBOMe adverse-reaction reports reporting seizures in 40% of cases and deaths in 3%. Clinical trials of MDMA or psilocybin for psychiatric disorders are reported to have had no serious drug-related adverse events, although these trials deliberately excluded concurrent serotonergic medications. Drug–drug interaction risk stratification: The authors emphasise that ST risk depends on specific pharmacology rather than a blanket ‘‘any serotonergic combination’’ rule. Key mechanisms that increase intrasynaptic 5-HT—SERT inhibition (SRIs), carrier-mediated 5-HT release (SRAs), and inhibition of monoamine metabolism (MAOIs)—are central to risk. In general: combinations of an SRA (for example MDMA) with an MAOI are high risk for hypertensive crisis or ST and are contraindicated. Phenethylamines (MDMA and some cathinones) tend to release multiple monoamines and carry both serotonergic and sympathomimetic risks, increasing hyperthermia, cardiovascular stress and seizure risk, and sometimes encouraging stacked dosing patterns. Classic tryptamines (DMT, psilocybin, LSD) typically do not increase intrasynaptic 5-HT to the same extent and are described as relatively safer with acute MAOI co-ingestion, although exceptions exist. Partial agonism and mechanistic assays: The review reports in vitro data on 5-HT2A activation efficacy relative to 5-HT: psilocin 16% ± 8, LSD 28% ± 10 and DMT 40% ± 11 of 5-HT activation in FLIPR calcium assays. The authors propose that partial agonism and functional selectivity (biased agonism) at 5-HT2A may explain why classic tryptamines infrequently cause ST even at high doses—the post-synaptic signalling cascades activated by these ligands do not reach the same maximal levels as endogenous 5-HT. By contrast, 5-MeO-DMT shows very strong second-messenger activation in some assays and has case reports of ST when co-ingested with MAOI-containing harmala alkaloids; harmala alkaloids also inhibit CYP2D6 and can increase systemic exposure to certain tryptamines. Specific combinations and clinical observations: Small clinical trials combining SRIs and MDMA have often found attenuated subjective and physical effects of MDMA when SRI occupancy of SERT is present, potentially translating into reduced therapeutic benefit. The extracted text cites a finding of lower PTSD response among participants who had recently tapered antidepressants prior to MDMA-assisted therapy, noting a mean of 25.1 days in the reported sample; the extraction does not clearly report the full context. The authors restate that antidepressants (SSRIs, SNRIs, TCAs) are contraindicated with MAOIs, but that combining standard doses of non-MAOI serotonergic antidepressants with non-MAOI psychedelics is predicted to carry little to no risk of severe ST; however, subjective psychedelic effects may be blunted. Microdosing of non-MAOI psychedelics is predicted to be lower risk still, although long-term microdosing with agents that strongly agonise 5-HT2B could raise concerns about valvular heart disease and merits further surveillance. Management recommendations: Initial management is discontinuation of serotonergic agents and supportive care (oxygen, IV fluids), environmental calming and avoidance of physical restraint. Benzodiazepines (lorazepam 2–4 mg, diazepam 5–10 mg) are recommended for agitation; short-acting IV antihypertensives (esmolol, nitroprusside) may be used for severe hypertension or tachycardia. For persistent moderate–severe ST, 5-HT2A antagonism with cyproheptadine is recommended: an initial 12 mg dose followed by 2 mg every 2 hours until clinical response. Severe hyperthermia (> 41.1 °C) requires immediate paralysis with non-depolarising neuromuscular blockade (e.g., vecuronium), intubation and active cooling. The role of dantrolene for MDMA-related hyperthermia (> 40 °C) is noted as under investigation with some reported survival benefit in case reports.

Malcolm and colleagues interpret their synthesis to mean that serotonin-related adverse reactions should be conceptualised as a spectrum, with true serotonin syndrome representing the most severe and typically uncommon extreme. They reiterate that clinically significant ST most often arises from overdoses or from specific pharmacological interactions—chiefly combinations of agents that increase intrasynaptic serotonin together with MAO inhibition. The review positions these conclusions relative to earlier work by emphasising mechanistic pharmacology (SERT/VMAT2 activity, MAO inhibition, 5-HT2A receptor efficacy and biased signalling) as the key determinants of risk, rather than simple shared ‘‘serotonergic’’ labelling. The authors acknowledge that many psychedelics produce transient serotonin-related somatic effects at therapeutic doses and that serious adverse events are rare in both observational data and controlled trials, although the latter deliberately exclude coadministration of serotonergic medications. They note exceptions and cautions: novel psychoactive substances (e.g., NBOMe) and certain tryptamines (notably 5‑MeO‑DMT) have been implicated in more severe outcomes, particularly when combined with MAOI-containing preparations or when misrepresented in illicit markets. The review highlights gaps and uncertainties—poison-control and case-report data may under- or over-represent true risk, and the extraction does not document a formal systematic method for literature inclusion—so the conclusions are presented as risk stratification based on available pharmacology and reported clinical cases. From a clinical perspective, the authors suggest practical implications: clinicians should assess timelines and specific drug exposures when considering ST; use Hunter criteria for diagnosis; avoid physical restraint; and manage ST with supportive care, benzodiazepines, cyproheptadine for persistent cases, and aggressive cooling and paralysis for extreme hyperthermia. They also flag that concomitant use of standard-dose non-MAOI antidepressants with non-MAOI psychedelics is likely low risk for severe ST but may blunt subjective psychedelic effects and potentially reduce therapeutic benefit. Finally, the authors recommend attention to pharmacodynamic and pharmacokinetic interactions (including MAO and CYP inhibition) and further study where evidence is limited.

Serotonin-related adverse reactions span from mild, expected symptoms to rare but life‑threatening serotonin syndrome. True ST typically occurs in overdose situations or when drugs that raise intrasynaptic serotonin are combined with MAOIs. Most serotonergic psychedelics at therapeutic doses produce transient somatic effects; case reports of ST are exceedingly rare. Combining serotonergic psychotropics that do not include MAOIs with psychedelics that also lack MAOI activity is described as low risk for severe ST, although vigilance is required and certain combinations (for example, MAOI plus SRA) remain contraindicated. Immediate medical attention is warranted for myoclonus, extreme and fluctuating vital signs, marked agitation or coma, muscle rigidity, pronounced hyperthermia and seizure activity.